Sub menu

 
 

Vifor Pharma Pty Ltd

Regulatory activities for this sponsor.

Type

Date

23 result(s) found, displaying 1 to 10

  • AusPAR: Korsuva

    Australian Public Assessment Report (AusPAR)
    Korsuva (difelikefalin) is approved to treat moderate-to-severe pruritus associated with chronic kidney disease in adults on haemodialysis.

  • AusPAR: Tavneos

    Australian Public Assessment Report (AusPAR)
    Tavneos (avacopan), in combination with a rituximab- or cyclophosphamide-based regimen, has been approved for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis

  • Tavneos

    Prescription medicine decision summary
    TGA decision: Tavneos (avacopan) is approved to treat adults with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]).

  • Korsuva

    Prescription medicine decision summary
    Korsuva (difelikefalin acetate) is approved to treat chronic kidney disease

  • AusPAR: Ferric carboxymaltose

    Australian Public Assessment Report (AusPAR)
    Australian Public Assessment Report for Ferric carboxymaltose

Help us improve the Therapeutic Goods Administration site